Comparative biomarker analysis of PALOMA-2/3 trials for palbociclib
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Comparative biomarker analysis of PALOMA-2/3 trials for palbociclib
Authors
Keywords
-
Journal
npj Precision Oncology
Volume 6, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2022-08-16
DOI
10.1038/s41698-022-00297-1
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer: Results from the adaptively randomized I-SPY2 trial
- (2021) Lajos Pusztai et al. CANCER CELL
- Overall survival (OS) with palbociclib (PAL) + fulvestrant (FUL) in women with hormone receptor–positive (HR+), human epidermal growth factor receptor 2–negative (HER2–) advanced breast cancer (ABC): Updated analyses from PALOMA-3.
- (2021) Massimo Cristofanilli et al. JOURNAL OF CLINICAL ONCOLOGY
- Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer
- (2020) Rita Nanda et al. JAMA Oncology
- Exhausted T cell signature predicts immunotherapy response in ER-positive breast cancer
- (2020) Manuela Terranova-Barberio et al. Nature Communications
- Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up
- (2019) H. S. Rugo et al. BREAST CANCER RESEARCH AND TREATMENT
- Cyclin E1 Expression and Palbociclib Efficacy in Previously Treated Hormone Receptor–Positive Metastatic Breast Cancer
- (2019) Nicholas C. Turner et al. JOURNAL OF CLINICAL ONCOLOGY
- The T-cell-inflamed tumor microenvironment as a paradigm for immunotherapy drug development
- (2019) Daniel J Olson et al. Immunotherapy
- Current Landscape of Immunotherapy in Breast Cancer
- (2019) Sylvia Adams et al. JAMA Oncology
- Biomarker Analyses of Response to Cyclin Dependent Kinase 4/6 Inhibition and Endocrine Therapy in Women With Treatment-Naïve Metastatic Breast Cancer
- (2019) Richard S. Finn et al. CLINICAL CANCER RESEARCH
- The PI3K/AKT/mTOR and CDK4/6 Pathways in Endocrine Resistant HR+/HER2− Metastatic Breast Cancer: Biological Mechanisms and New Treatments
- (2019) Daniele Presti et al. Cancers
- Palbociclib as single agent or in combination with the endocrine therapy received before disease progression for estrogen receptor-positive, HER2-negative metastatic breast cancer: TREnd trial
- (2018) L Malorni et al. ANNALS OF ONCOLOGY
- Abstract PD6-13: Phase 1b/2 study to evaluate eribulin mesylate in combination with pembrolizumab in patients with metastatic triple-negative breast cancer
- (2018) SM Tolaney et al. CANCER RESEARCH
- Overcoming endocrine resistance in hormone receptor–positive breast cancer
- (2018) A. AlFakeeh et al. Current Oncology
- T Cell–Inflamed versus Non-T Cell–Inflamed Tumors: A Conceptual Framework for Cancer Immunotherapy Drug Development and Combination Therapy Selection
- (2018) Jonathan A. Trujillo et al. Cancer Immunology Research
- Complex interplay between tumor microenvironment and cancer therapy
- (2018) Minhong Shen et al. Frontiers of Medicine
- Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study
- (2018) S Adams et al. ANNALS OF ONCOLOGY
- Resistance to endocrine therapy in breast cancer: molecular mechanisms and future goals
- (2018) Małgorzata Szostakowska et al. BREAST CANCER RESEARCH AND TREATMENT
- Predictors of prolonged benefit from palbociclib plus fulvestrant in women with endocrine-resistant hormone receptor–positive/human epidermal growth factor receptor 2–negative metastatic breast cancer in PALOMA-3
- (2018) Massimo Cristofanilli et al. EUROPEAN JOURNAL OF CANCER
- Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods
- (2018) J. Ferlay et al. INTERNATIONAL JOURNAL OF CANCER
- Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer
- (2018) Nicholas C. Turner et al. NEW ENGLAND JOURNAL OF MEDICINE
- Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer
- (2018) Peter Schmid et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pan-tumor genomic biomarkers for PD-1 checkpoint blockade–based immunotherapy
- (2018) Razvan Cristescu et al. SCIENCE
- IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade
- (2017) Mark Ayers et al. JOURNAL OF CLINICAL INVESTIGATION
- Palbociclib: A Review in HR-Positive, HER2-Negative, Advanced or Metastatic Breast Cancer
- (2017) Esther S. Kim et al. Targeted Oncology
- CDK4/6 Inhibition Augments Antitumor Immunity by Enhancing T-cell Activation
- (2017) Jiehui Deng et al. Cancer Discovery
- Pan-cancer Immunogenomic Analyses Reveal Genotype-Immunophenotype Relationships and Predictors of Response to Checkpoint Blockade
- (2017) Pornpimol Charoentong et al. Cell Reports
- The immune system and hormone-receptor positive breast cancer: Is it really a dead end?
- (2016) Maria Vittoria Dieci et al. CANCER TREATMENT REVIEWS
- Mechanisms of tumor escape in the context of the T-cell-inflamed and the non-T-cell-inflamed tumor microenvironment
- (2016) Stefani Spranger INTERNATIONAL IMMUNOLOGY
- Palbociclib and Letrozole in Advanced Breast Cancer
- (2016) Richard S. Finn et al. NEW ENGLAND JOURNAL OF MEDICINE
- The changing role of ER in endocrine resistance
- (2015) Agostina Nardone et al. BREAST
- Oral Selective Estrogen Receptor Downregulators (SERDs), a Breakthrough Endocrine Therapy for Breast Cancer
- (2015) Donald P. McDonnell et al. JOURNAL OF MEDICINAL CHEMISTRY
- Palbociclib in Hormone-Receptor–Positive Advanced Breast Cancer
- (2015) Nicholas C. Turner et al. NEW ENGLAND JOURNAL OF MEDICINE
- Absolute Assignment of Breast Cancer Intrinsic Molecular Subtype
- (2014) Eric R. Paquet et al. JNCI-Journal of the National Cancer Institute
- GSVA: gene set variation analysis for microarray and RNA-Seq data
- (2013) Sonja Hänzelmann et al. BMC BIOINFORMATICS
- Up-Regulation of PD-L1, IDO, and Tregs in the Melanoma Tumor Microenvironment Is Driven by CD8+ T Cells
- (2013) S. Spranger et al. Science Translational Medicine
- Treatment-induced damage to the tumor microenvironment promotes prostate cancer therapy resistance through WNT16B
- (2012) Yu Sun et al. NATURE MEDICINE
- Fast gapped-read alignment with Bowtie 2
- (2012) Ben Langmead et al. NATURE METHODS
- RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome
- (2011) Bo Li et al. BMC BIOINFORMATICS
- Mechanisms of Endocrine Resistance in Breast Cancer
- (2010) C. Kent Osborne et al. Annual Review of Medicine
- Supervised Risk Predictor of Breast Cancer Based on Intrinsic Subtypes
- (2009) Joel S. Parker et al. JOURNAL OF CLINICAL ONCOLOGY
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now